샘플 요청 목록

 카트 문의
시장보고서
상품코드
2029165

세균성 폐렴 시장 : 시장 인사이트, 경쟁 구도 및 시장 예측(2033년)

Bacterial Pneumonia Market Insights, Competitive Landscape, and Market Forecast - 2033
발행일: | 리서치사: 구분자 Fairfield Market Research | 페이지 정보: 영문 200 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



가격
Unprintable PDF & Excel (Single User License) help
PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.
US $ 4,995 금액 안내 화살표 ￦ 7,559,000
Unprintable PDF & Excel (Multi User License upto 5 users) help
PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.
US $ 8,495 금액 안내 화살표 ￦ 12,857,000
Printable PDF & Excel (Enterprise License above 5 users) help
PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,600 금액 안내 화살표 ￦ 16,043,000
카드담기
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전 세계 의료 시스템이 호흡기 감염을 보다 효과적으로 관리하기 위한 노력을 강화하고 있는 가운데, 세계 세균성 폐렴 시장은 꾸준히 성장하고 있습니다. 세균성 폐렴은 특히 노인, 면역력이 저하된 사람, 기저질환이 있는 환자들 사이에서 여전히 심각한 공중보건 문제가 되고 있습니다. 인식의 증가, 진단 능력의 향상, 치료 옵션의 확대가 결합되어 시장 전망을 더욱 견고하게 만들고 있습니다. 시장 규모는 2026년 25억 달러에 달할 것으로 추정되며, 2033년까지 42억 달러로 성장하여 예측 기간 동안 7.60%의 CAGR을 기록할 것으로 예상됩니다. 이러한 상승 추세는 빠른 진단, 첨단 치료법 및 더 나은 환자 치료 솔루션에 대한 수요 증가를 반영합니다.

시장 인사이트

세균성 폐렴 시장은 진단과 치료법의 발전에 따라 크게 변화하고 있습니다. 신속 진단 기술, 특히 PCR 검사 및 첨단 영상 진단 기술로의 전환으로 병원체를 보다 신속하고 정확하게 식별할 수 있게 되었습니다. 이러한 개선으로 임상의는 표적 치료를 시작할 수 있게 되어 합병증 감소와 회복률 향상으로 이어지고 있습니다.

동시에 제약 분야의 혁신도 치료 프로토콜을 재구성하는 데 있어 매우 중요한 역할을 하고 있습니다. 광범위 및 차세대 항생제 개발은 계속 변화하는 박테리아의 내성 패턴에 대응하기 위해 노력하고 있습니다. 또한, 의료 서비스 제공자들은 진단, 치료, 모니터링을 결합한 통합 치료 모델을 점점 더 많이 채택하여 환자의 결과를 개선하고 있습니다. 백신 접종 프로그램과 같은 예방 전략도 감염률 감소와 장기적인 질병 관리 지원을 통해 간접적으로 기여하고 있습니다.

촉진요인

전 세계적으로 증가하고 있는 호흡기 감염증의 발생률은 세균성 폐렴 시장의 주요 시장 촉진요인으로 작용하고 있습니다. 대기오염의 악화, 흡연 습관, 고령화 등의 요인이 사람들의 감염 위험을 높이는 요인으로 작용하고 있습니다. 병원내 감염도 증가 추세에 있어 효과적인 치료 솔루션에 대한 수요가 더욱 증가하고 있습니다.

또 다른 중요한 성장 요인은 항균제 내성 문제가 심각해지고 있다는 점입니다. 이에 따라 내성균주를 표적으로 삼을 수 있는 혁신적인 약물 연구개발에 대한 투자가 증가하고 있습니다. 정부와 의료 기관은 항생제의 올바른 사용(안티바이오틱스 스튜어드십)을 개선하기 위한 노력을 적극적으로 지원하고 있으며, 이는 이 분야의 혁신을 더욱 촉진하고 있습니다.

개발도상국의 의료 인프라 확충도 시장 성장을 견인하고 있습니다. 병원, 진단 센터, 치료 시설에 대한 접근성이 개선되면서 조기 발견과 조기 개입이 가능해졌고, 이는 결국 세균성 폐렴 치료제에 대한 수요를 증가시키고 있습니다.

비즈니스 기회

이 시장은 의약품, 진단, 의료 서비스 분야에서 큰 기회를 제공하고 있습니다. 내성 병원균을 표적으로 하는 새로운 항생제 및 대체 치료법 개발은 업계 관계자들이 지속적으로 집중하고 있는 분야입니다. 정밀의료와 병원체 특이적 치료 접근법에 투자하는 기업들은 강력한 성장 잠재력을 가지고 있는 것으로 판단됩니다.

진단 기술 혁신도 또 다른 주요 기회 영역입니다. 특히 응급의료 및 중환자 치료 현장에서 신속한 현장 검사 솔루션에 대한 수요가 증가하고 있습니다. 인공지능(AI)과 영상 진단, 임상 검사를 통합한 기술은 임상적 판단의 효율성과 정확성을 향상시킬 것으로 기대되고 있습니다.

신흥국에서는 의료체계의 개선과 감염병에 대한 인식이 높아짐에 따라 미개척된 큰 잠재력이 존재합니다. 기업들은 전략적 제휴와 지리적 사업 확장을 통해 이러한 고성장 지역에서 입지를 강화하고 있습니다. 재택 치료의 확대 추세도 새로운 길을 열고 있으며, 휴대용 진단 도구와 외래 치료 옵션이 인기를 끌고 있습니다.

지역별 분석

북미는 선진화된 의료 인프라, 높은 의료비 지출, 그리고 주요 기업의 강력한 입지를 바탕으로 세균성 폐렴 시장을 선도하고 있습니다. 이 지역은 혁신적인 치료 솔루션의 조기 도입과 확립된 진단 시스템의 혜택을 누리고 있습니다.

유럽은 탄탄한 의료 체계와 항균제 내성 관리에 대한 관심 증가에 힘입어 여전히 큰 시장 점유율을 유지하고 있습니다. 독일, 영국, 프랑스 등의 국가들은 강력한 연구 및 의료 역량으로 최전선에 서 있습니다.

아시아태평양은 인구 증가, 호흡기 감염 발생률 증가, 의료 인프라의 지속적인 개선에 힘입어 가장 빠르게 성장하는 지역으로 부상하고 있습니다. 중국, 인도 등의 국가에서는 의료서비스에 대한 접근성 확대와 인식의 증가로 인해 괄목할 만한 성장을 보이고 있습니다.

라틴아메리카와 중동 및 아프리카는 의료 인프라 개선과 의료 투자 증가에 힘입어 시장이 점차 확대되고 있습니다. 이들 지역은 향후 몇 년 동안 유망한 성장 기회를 제공할 것으로 예상됩니다.

주요 기업

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Bayer AG
  • AstraZeneca plc
  • Novartis AG
  • GlaxoSmithKline plc(GSK)
  • bioMerieux SA
  • Shionogi & Co., Ltd.
  • Wockhardt Limited
  • Innoviva, Inc.
  • Eagle Pharmaceuticals, Inc.
  • Basilea Pharmaceutica Ltd.
  • Paratek Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.

이들 기업은 시장에서의 경쟁 우위를 유지하기 위해 제품 파이프라인 확대, 연구 역량 강화, 전략적 제휴 구축에 적극 나서고 있습니다.

세분화

유형별

  • 시중 폐렴(CAP)
  • 병원 내 폐렴(HAP)
  • 인공호흡기 관련 폐렴(VAP)
  • 흡인성 폐렴
  • 기타

병원체별

  • 폐렴구균
  • 인플루엔자균
  • 황색포도상구균
  • 그람 음성균
  • 기타

진단 방법별

  • 미생물학적 배양
  • 중합효소 연쇄 반응(PCR)
  • 흉부 엑스레이/영상 검사
  • 혈액 검사
  • 객담 검사

유통 채널별

  • 병원 약국
  • 소매 약국
  • 온라인 약국

최종사용자별

  • 병원
  • 진료소
  • 진단센터
  • 재택의료

지역별

  • 북미
  • 북미
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

목차

제1장 주요 요약

제2장 시장 개요

제3장 세계의 세균성 폐렴 시장 전망, 2020-2033년

제4장 북미의 세균성 폐렴 시장 전망, 2020-2033년

제5장 유럽의 세균성 폐렴 시장 전망, 2020-2033년

제6장 아시아태평양의 세균성 폐렴 시장 전망, 2020-2033년

제7장 라틴아메리카의 세균성 폐렴 시장 전망, 2020-2033년

제8장 중동 및 아프리카의 세균성 폐렴 시장 전망, 2020-2033년

제9장 경쟁 구도

제10장 부록

KSM 26.05.20

The global bacterial pneumonia market is gaining steady momentum as healthcare systems worldwide intensify efforts to manage respiratory infections more effectively. Bacterial pneumonia continues to be a significant public health concern, particularly among elderly populations, individuals with weakened immune systems, and patients with underlying chronic diseases. Growing awareness, improved diagnostic capabilities, and expanding treatment options are collectively strengthening the market outlook. The market is estimated to reach US$ 2.5 billion in 2026 and is projected to grow to US$ 4.2 billion by 2033, registering a CAGR of 7.60% over the forecast period. This upward trajectory reflects increasing demand for timely diagnosis, advanced therapeutics, and better patient care solutions.

Market Insights

The bacterial pneumonia market is undergoing notable transformation with advancements in both diagnostics and therapeutics. The shift toward rapid diagnostic technologies, particularly PCR-based testing and advanced imaging techniques, is enabling faster and more precise identification of pathogens. This improvement is helping clinicians initiate targeted treatments, reducing complications and improving recovery rates.

At the same time, pharmaceutical innovation is playing a crucial role in reshaping treatment protocols. The development of broad-spectrum and next-generation antibiotics is addressing evolving bacterial resistance patterns. Additionally, healthcare providers are increasingly adopting integrated care models that combine diagnostics, treatment, and monitoring, ensuring better patient outcomes. Preventive strategies such as vaccination programs are also contributing indirectly by lowering infection rates and supporting long-term disease management.

Drivers

The rising incidence of respiratory infections globally remains a primary driver for the bacterial pneumonia market. Factors such as increasing air pollution, smoking habits, and aging demographics are contributing to higher susceptibility among populations. Hospital-acquired infections are also on the rise, further increasing the demand for effective treatment solutions.

Another critical growth driver is the growing challenge of antimicrobial resistance. This has led to increased investments in research and development for innovative drugs capable of targeting resistant bacterial strains. Governments and healthcare organizations are actively supporting initiatives aimed at improving antibiotic stewardship, which is further encouraging innovation in this space.

Expanding healthcare infrastructure in developing regions is also fueling market growth. Improved access to hospitals, diagnostic centers, and treatment facilities is enabling earlier detection and intervention, ultimately boosting demand for bacterial pneumonia therapies.

Business Opportunity

The market offers substantial opportunities across pharmaceuticals, diagnostics, and healthcare services. The development of novel antibiotics and alternative therapies targeting resistant pathogens remains a key area of focus for industry players. Companies investing in precision medicine and pathogen-specific treatment approaches are likely to see strong growth potential.

Diagnostic innovation is another major opportunity area. The demand for rapid, point-of-care testing solutions is increasing, particularly in emergency and critical care settings. Technologies integrating artificial intelligence with imaging and laboratory diagnostics are expected to enhance efficiency and accuracy in clinical decision-making.

Emerging economies present significant untapped potential due to improving healthcare systems and rising awareness about infectious diseases. Strategic collaborations and geographic expansion are enabling companies to strengthen their presence in these high-growth regions. The growing trend of home-based care is also creating new avenues, with portable diagnostic tools and outpatient treatment options gaining popularity.

Region Analysis

North America continues to lead the bacterial pneumonia market, supported by advanced healthcare infrastructure, high healthcare spending, and strong presence of leading pharmaceutical companies. The region benefits from early adoption of innovative treatment solutions and well-established diagnostic systems.

Europe maintains a substantial market share, driven by robust healthcare frameworks and increasing focus on antimicrobial resistance management. Countries such as Germany, the United Kingdom, and France are at the forefront due to their strong research and healthcare capabilities.

Asia-Pacific is emerging as the fastest-growing region, fueled by rising population, increasing incidence of respiratory infections, and ongoing improvements in healthcare infrastructure. Countries including China and India are witnessing significant growth due to expanding access to healthcare services and growing awareness.

Latin America and the Middle East & Africa are gradually expanding markets, supported by improving medical infrastructure and increased healthcare investments. These regions are expected to offer promising growth opportunities over the coming years.

Key Players

  • Pfizer Inc.
  • Merck & Co., Inc.
  • AbbVie Inc.
  • Bayer AG
  • AstraZeneca plc
  • Novartis AG
  • GlaxoSmithKline plc (GSK)
  • bioMerieux SA
  • Shionogi & Co., Ltd.
  • Wockhardt Limited
  • Innoviva, Inc.
  • Eagle Pharmaceuticals, Inc.
  • Basilea Pharmaceutica Ltd.
  • Paratek Pharmaceuticals, Inc.
  • Melinta Therapeutics, Inc.

These companies are actively focusing on expanding their product pipelines, strengthening research capabilities, and forming strategic alliances to maintain a competitive edge in the market.

Segmentation

By Type

  • Community-Acquired Pneumonia (CAP)
  • Hospital-Acquired Pneumonia (HAP)
  • Ventilator-Associated Pneumia (VAP)
  • Aspiration Pneumonia
  • Others

By Pathogen Type

  • Streptococcus pneumoniae
  • Haemophilus influenzae
  • Staphylococcus aureus
  • Gram-negative bacteria
  • Others

By Diagnosis Method

  • Microbiological Culture
  • Polymerase Chain Reaction (PCR)
  • Chest X-ray / Imaging
  • Blood Tests
  • Sputum Analysis

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User

  • Hospitals
  • Clinics
  • Diagnostic Centers
  • Homecare Settings

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Bacterial Pneumonia Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Five Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global Bacterial Pneumonia Market Outlook, 2020-2033

  • 3.1. Global Bacterial Pneumonia Market Outlook, by Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Community-Acquired Pneumonia (CAP)
    • 3.1.2. Hospital-Acquired Pneumonia (HAP)
    • 3.1.3. Ventilator-Associated Pneumia (VAP)
    • 3.1.4. Aspiration Pneumonia
    • 3.1.5. Others
  • 3.2. Global Bacterial Pneumonia Market Outlook, by Pathogen Type, Value (US$ Bn), 2020-2033
    • 3.2.1. Streptococcus pneumoniae
    • 3.2.2. Haemophilus influenzae
    • 3.2.3. Staphylococcus aureus
    • 3.2.4. Gram-negative bacteria
    • 3.2.5. Others
  • 3.3. Global Bacterial Pneumonia Market Outlook, by Diagnosis Method, Value (US$ Bn), 2020-2033
    • 3.3.1. Microbiological Culture
    • 3.3.2. Polymerase Chain Reaction (PCR)
    • 3.3.3. Chest X-ray / Imaging
    • 3.3.4. Blood Tests
    • 3.3.5. Sputum Analysis
  • 3.4. Global Bacterial Pneumonia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 3.4.1. Hospital Pharmacies
    • 3.4.2. Retail Pharmacies
    • 3.4.3. Online Pharmacies
  • 3.5. Global Bacterial Pneumonia Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.5.1. Hospitals
    • 3.5.2. Clinics
    • 3.5.3. Diagnostic Centers
    • 3.5.4. Homecare Settings
  • 3.6. Global Bacterial Pneumonia Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.6.1. North America
    • 3.6.2. Europe
    • 3.6.3. Asia Pacific
    • 3.6.4. Latin America
    • 3.6.5. Middle East & Africa

4. North America Bacterial Pneumonia Market Outlook, 2020-2033

  • 4.1. North America Bacterial Pneumonia Market Outlook, by Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Community-Acquired Pneumonia (CAP)
    • 4.1.2. Hospital-Acquired Pneumonia (HAP)
    • 4.1.3. Ventilator-Associated Pneumia (VAP)
    • 4.1.4. Aspiration Pneumonia
    • 4.1.5. Others
  • 4.2. North America Bacterial Pneumonia Market Outlook, by Pathogen Type, Value (US$ Bn), 2020-2033
    • 4.2.1. Streptococcus pneumoniae
    • 4.2.2. Haemophilus influenzae
    • 4.2.3. Staphylococcus aureus
    • 4.2.4. Gram-negative bacteria
    • 4.2.5. Others
  • 4.3. North America Bacterial Pneumonia Market Outlook, by Diagnosis Method, Value (US$ Bn), 2020-2033
    • 4.3.1. Microbiological Culture
    • 4.3.2. Polymerase Chain Reaction (PCR)
    • 4.3.3. Chest X-ray / Imaging
    • 4.3.4. Blood Tests
    • 4.3.5. Sputum Analysis
  • 4.4. North America Bacterial Pneumonia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 4.4.1. Hospital Pharmacies
    • 4.4.2. Retail Pharmacies
    • 4.4.3. Online Pharmacies
  • 4.5. North America Bacterial Pneumonia Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.5.1. Hospitals
    • 4.5.2. Clinics
    • 4.5.3. Diagnostic Centers
    • 4.5.4. Homecare Settings
  • 4.6. North America Bacterial Pneumonia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.6.1. U.S. Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 4.6.2. U.S. Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 4.6.3. U.S. Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 4.6.4. U.S. Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 4.6.5. U.S. Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 4.6.6. Canada Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 4.6.7. Canada Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 4.6.8. Canada Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 4.6.9. Canada Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 4.6.10. Canada Bacterial Pneumonia Market Outlook, by End User, 2020-2033
  • 4.7. BPS Analysis/Market Attractiveness Analysis

5. Europe Bacterial Pneumonia Market Outlook, 2020-2033

  • 5.1. Europe Bacterial Pneumonia Market Outlook, by Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Community-Acquired Pneumonia (CAP)
    • 5.1.2. Hospital-Acquired Pneumonia (HAP)
    • 5.1.3. Ventilator-Associated Pneumia (VAP)
    • 5.1.4. Aspiration Pneumonia
    • 5.1.5. Others
  • 5.2. Europe Bacterial Pneumonia Market Outlook, by Pathogen Type, Value (US$ Bn), 2020-2033
    • 5.2.1. Streptococcus pneumoniae
    • 5.2.2. Haemophilus influenzae
    • 5.2.3. Staphylococcus aureus
    • 5.2.4. Gram-negative bacteria
    • 5.2.5. Others
  • 5.3. Europe Bacterial Pneumonia Market Outlook, by Diagnosis Method, Value (US$ Bn), 2020-2033
    • 5.3.1. Microbiological Culture
    • 5.3.2. Polymerase Chain Reaction (PCR)
    • 5.3.3. Chest X-ray / Imaging
    • 5.3.4. Blood Tests
    • 5.3.5. Sputum Analysis
  • 5.4. Europe Bacterial Pneumonia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Europe Bacterial Pneumonia Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.5.1. Hospitals
    • 5.5.2. Clinics
    • 5.5.3. Diagnostic Centers
    • 5.5.4. Homecare Settings
  • 5.6. Europe Bacterial Pneumonia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.6.1. Germany Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 5.6.2. Germany Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 5.6.3. Germany Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 5.6.4. Germany Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.5. Germany Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 5.6.6. Italy Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 5.6.7. Italy Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 5.6.8. Italy Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 5.6.9. Italy Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.10. Italy Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 5.6.11. France Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 5.6.12. France Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 5.6.13. France Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 5.6.14. France Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.15. France Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 5.6.16. U.K. Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 5.6.17. U.K. Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 5.6.18. U.K. Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 5.6.19. U.K. Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.20. U.K. Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 5.6.21. Spain Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 5.6.22. Spain Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 5.6.23. Spain Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 5.6.24. Spain Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.25. Spain Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 5.6.26. Russia Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 5.6.27. Russia Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 5.6.28. Russia Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 5.6.29. Russia Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.30. Russia Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 5.6.31. Rest of Europe Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 5.6.32. Rest of Europe Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 5.6.33. Rest of Europe Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 5.6.34. Rest of Europe Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 5.6.35. Rest of Europe Bacterial Pneumonia Market Outlook, by End User, 2020-2033
  • 5.7. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Bacterial Pneumonia Market Outlook, 2020-2033

  • 6.1. Asia Pacific Bacterial Pneumonia Market Outlook, by Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Community-Acquired Pneumonia (CAP)
    • 6.1.2. Hospital-Acquired Pneumonia (HAP)
    • 6.1.3. Ventilator-Associated Pneumia (VAP)
    • 6.1.4. Aspiration Pneumonia
    • 6.1.5. Others
  • 6.2. Asia Pacific Bacterial Pneumonia Market Outlook, by Pathogen Type, Value (US$ Bn), 2020-2033
    • 6.2.1. Streptococcus pneumoniae
    • 6.2.2. Haemophilus influenzae
    • 6.2.3. Staphylococcus aureus
    • 6.2.4. Gram-negative bacteria
    • 6.2.5. Others
  • 6.3. Asia Pacific Bacterial Pneumonia Market Outlook, by Diagnosis Method, Value (US$ Bn), 2020-2033
    • 6.3.1. Microbiological Culture
    • 6.3.2. Polymerase Chain Reaction (PCR)
    • 6.3.3. Chest X-ray / Imaging
    • 6.3.4. Blood Tests
    • 6.3.5. Sputum Analysis
  • 6.4. Asia Pacific Bacterial Pneumonia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Asia Pacific Bacterial Pneumonia Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.5.1. Hospitals
    • 6.5.2. Clinics
    • 6.5.3. Diagnostic Centers
    • 6.5.4. Homecare Settings
  • 6.6. Asia Pacific Bacterial Pneumonia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.6.1. China Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 6.6.2. China Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 6.6.3. China Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 6.6.4. China Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.5. China Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 6.6.6. Japan Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 6.6.7. Japan Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 6.6.8. Japan Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 6.6.9. Japan Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.10. Japan Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 6.6.11. South Korea Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 6.6.12. South Korea Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 6.6.13. South Korea Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 6.6.14. South Korea Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.15. South Korea Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 6.6.16. India Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 6.6.17. India Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 6.6.18. India Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 6.6.19. India Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.20. India Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 6.6.21. Southeast Asia Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 6.6.22. Southeast Asia Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 6.6.23. Southeast Asia Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 6.6.24. Southeast Asia Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.25. Southeast Asia Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 6.6.26. Rest of SAO Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 6.6.27. Rest of SAO Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 6.6.28. Rest of SAO Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 6.6.29. Rest of SAO Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 6.6.30. Rest of SAO Bacterial Pneumonia Market Outlook, by End User, 2020-2033
  • 6.7. BPS Analysis/Market Attractiveness Analysis

7. Latin America Bacterial Pneumonia Market Outlook, 2020-2033

  • 7.1. Latin America Bacterial Pneumonia Market Outlook, by Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Community-Acquired Pneumonia (CAP)
    • 7.1.2. Hospital-Acquired Pneumonia (HAP)
    • 7.1.3. Ventilator-Associated Pneumia (VAP)
    • 7.1.4. Aspiration Pneumonia
    • 7.1.5. Others
  • 7.2. Latin America Bacterial Pneumonia Market Outlook, by Pathogen Type, Value (US$ Bn), 2020-2033
    • 7.2.1. Streptococcus pneumoniae
    • 7.2.2. Haemophilus influenzae
    • 7.2.3. Staphylococcus aureus
    • 7.2.4. Gram-negative bacteria
    • 7.2.5. Others
  • 7.3. Latin America Bacterial Pneumonia Market Outlook, by Diagnosis Method, Value (US$ Bn), 2020-2033
    • 7.3.1. Microbiological Culture
    • 7.3.2. Polymerase Chain Reaction (PCR)
    • 7.3.3. Chest X-ray / Imaging
    • 7.3.4. Blood Tests
    • 7.3.5. Sputum Analysis
  • 7.4. Latin America Bacterial Pneumonia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Latin America Bacterial Pneumonia Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.5.1. Hospitals
    • 7.5.2. Clinics
    • 7.5.3. Diagnostic Centers
    • 7.5.4. Homecare Settings
  • 7.6. Latin America Bacterial Pneumonia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.6.1. Brazil Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 7.6.2. Brazil Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 7.6.3. Brazil Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 7.6.4. Brazil Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.5. Brazil Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 7.6.6. Mexico Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 7.6.7. Mexico Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 7.6.8. Mexico Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 7.6.9. Mexico Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.10. Mexico Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 7.6.11. Argentina Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 7.6.12. Argentina Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 7.6.13. Argentina Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 7.6.14. Argentina Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.15. Argentina Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 7.6.16. Rest of LATAM Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 7.6.17. Rest of LATAM Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 7.6.18. Rest of LATAM Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 7.6.19. Rest of LATAM Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 7.6.20. Rest of LATAM Bacterial Pneumonia Market Outlook, by End User, 2020-2033
  • 7.7. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Bacterial Pneumonia Market Outlook, 2020-2033

  • 8.1. Middle East & Africa Bacterial Pneumonia Market Outlook, by Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Community-Acquired Pneumonia (CAP)
    • 8.1.2. Hospital-Acquired Pneumonia (HAP)
    • 8.1.3. Ventilator-Associated Pneumia (VAP)
    • 8.1.4. Aspiration Pneumonia
    • 8.1.5. Others
  • 8.2. Middle East & Africa Bacterial Pneumonia Market Outlook, by Pathogen Type, Value (US$ Bn), 2020-2033
    • 8.2.1. Streptococcus pneumoniae
    • 8.2.2. Haemophilus influenzae
    • 8.2.3. Staphylococcus aureus
    • 8.2.4. Gram-negative bacteria
    • 8.2.5. Others
  • 8.3. Middle East & Africa Bacterial Pneumonia Market Outlook, by Diagnosis Method, Value (US$ Bn), 2020-2033
    • 8.3.1. Microbiological Culture
    • 8.3.2. Polymerase Chain Reaction (PCR)
    • 8.3.3. Chest X-ray / Imaging
    • 8.3.4. Blood Tests
    • 8.3.5. Sputum Analysis
  • 8.4. Middle East & Africa Bacterial Pneumonia Market Outlook, by Distribution Channel, Value (US$ Bn), 2020-2033
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Middle East & Africa Bacterial Pneumonia Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.5.1. Hospitals
    • 8.5.2. Clinics
    • 8.5.3. Diagnostic Centers
    • 8.5.4. Homecare Settings
  • 8.6. Middle East & Africa Bacterial Pneumonia Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.6.1. GCC Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 8.6.2. GCC Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 8.6.3. GCC Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 8.6.4. GCC Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.5. GCC Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 8.6.6. South Africa Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 8.6.7. South Africa Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 8.6.8. South Africa Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 8.6.9. South Africa Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.10. South Africa Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 8.6.11. Egypt Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 8.6.12. Egypt Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 8.6.13. Egypt Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 8.6.14. Egypt Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.15. Egypt Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 8.6.16. Nigeria Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 8.6.17. Nigeria Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 8.6.18. Nigeria Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 8.6.19. Nigeria Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.20. Nigeria Bacterial Pneumonia Market Outlook, by End User, 2020-2033
    • 8.6.21. Rest of Middle East Bacterial Pneumonia Market Outlook, by Type, 2020-2033
    • 8.6.22. Rest of Middle East Bacterial Pneumonia Market Outlook, by Pathogen Type, 2020-2033
    • 8.6.23. Rest of Middle East Bacterial Pneumonia Market Outlook, by Diagnosis Method, 2020-2033
    • 8.6.24. Rest of Middle East Bacterial Pneumonia Market Outlook, by Distribution Channel, 2020-2033
    • 8.6.25. Rest of Middle East Bacterial Pneumonia Market Outlook, by End User, 2020-2033
  • 8.7. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Pfizer Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. Merck & Co., Inc.
    • 9.4.3. AbbVie Inc.
    • 9.4.4. Bayer AG
    • 9.4.5. AstraZeneca plc
    • 9.4.6. Novartis AG
    • 9.4.7. GlaxoSmithKline plc (GSK)
    • 9.4.8. bioMerieux SA
    • 9.4.9. Shionogi & Co., Ltd.
    • 9.4.10. Wockhardt Limited

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기